Mckesson Plasma And Biologics LLC

Mckesson Plasma and Biologics LLC, a for-profit limited liability company subsidiary of Mckesson Corporation, supplies specialty pharmaceuticals and medical supplies to federal healthcare agencies as a prime contractor on full-and-open purchase orders with no set-aside designation. Headquartered in Shepherdsville, Kentucky, the company operates exclusively as a prime vendor across its federal footprint — 711 awards spanning the past two decades, 100% prime contract work with no subcontract exposure.

Mckesson Plasma and Biologics LLC's federal capability centers on pharmaceutical and biologic product procurement for clinical and custodial healthcare settings. The vendor delivers named specialty medications including belzutifan 40mg capsules, Wayrilz 400mg tablets, YUTIQ implants, Fruquintinib capsules, Vonjo formulations, and Qutenza patches to Veterans Affairs regional service networks, as well as open-market pharmaceuticals and inmate medications to the Department of Justice Bureau of Prisons and Federal Correctional Institution network. A representative contract includes a $389,783 purchase order awarded by the NIH Clinical Center on November 4, 2021, for procurement of medical supplies. More recently, the vendor fulfilled a $18,262 purchase order from Veterans Integrated Service Network 20 for YUTIQ 3.5mm implants (August 3, 2026) and a $16,333 emergency procurement under Executive Order 14398 from VISN 22 for Wayrilz pharmaceutical products (June 30, 2026).

Customer concentration is heavily weighted to the Veterans Affairs healthcare system. The top five Department of Veterans Affairs regional networks account for 41% of all awards by count and 43% of combined potential value, led by Veterans Integrated Service Network 23 (65 awards, $1.7 million), VISN 19 (62 awards, $1.5 million), VISN 8 (53 awards, $1.5 million), and VISN 7 (51 awards, $1.5 million). The Department of Health and Human Services National Institutes of Health Clinical Center ranks second by dollar value (19 awards, $1.7 million combined potential value). The company serves 26 distinct customer agencies, including the Department of Justice Bureau of Prisons and Indian Health Service, but VA volume dominates both award frequency and dollar magnitude.

Activity has declined sharply — 11 awards in 2021, dropping to 3 awards in 2023 and 4 awards in 2026 — reflecting a transition from sustained pharmaceutical supply contracts to sparse, ad-hoc purchase orders. The recompete exposure in the next twenty-four months is negligible at $2 thousand across a single award. Award structure across the footprint emphasizes pharmaceutical preparation manufacturing (351 awards) and drugs and druggists' sundries merchant wholesale (274 awards) under PSC code Drugs and Biologicals (616 awards of 711 total). All awards carry firm fixed-price structures and no set-aside designation.